Last reviewed · How we verify
ARINA-1
ARINA-1 is a small molecule inhaled cystic fibrosis transmembrane conductance regulator (CFTR) corrector.
ARINA-1 is a small molecule inhaled cystic fibrosis transmembrane conductance regulator (CFTR) corrector. Used for Cystic fibrosis.
At a glance
| Generic name | ARINA-1 |
|---|---|
| Sponsor | Renovion, Inc. |
| Drug class | CFTR corrector |
| Target | CFTR |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | Phase 3 |
Mechanism of action
ARINA-1 works by correcting the folding and stability of the CFTR protein, allowing it to reach the cell surface and function properly. This leads to improved chloride ion transport across epithelial cell membranes, which helps to thin mucus and improve lung function in patients with cystic fibrosis.
Approved indications
- Cystic fibrosis
Common side effects
- Upper respiratory tract infection
- Nausea
- Headache
Key clinical trials
- Study to Evaluate ARINA-1 in the Prevention of Bronchiolitis Obliterans Progression in Participants With Bilateral Lung Transplant (PHASE3)
- Phase 2a, 28-day Investigational Use Study of ARINA-1 in Non-Cystic Fibrosis Bronchiectasis (NCFBE) With Excess Mucus and Cough (PHASE2)
- An Investigator-initiated Study to Evaluate Safety and Efficacy of ARINA-1 in People With a Tracheostomy (PHASE1)
- Use of ARINA-1 in an Intermediate Size Patient Population of Bilateral Lung Transplant Patients With CLAD Grade 0 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ARINA-1 CI brief — competitive landscape report
- ARINA-1 updates RSS · CI watch RSS
- Renovion, Inc. portfolio CI